+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Prescription Dermatology Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018-2026

  • ID: 4851357
  • Report
  • November 2018
  • Region: Global
  • 183 pages
  • Transparency Market Research
1 of 2

Prescription Dermatology Therapeutics Market - Overview

This report by Transparency Market Research analyzes the global prescription dermatology therapeutics market for the period between 2018 and 2026. An in-depth and unbiased market assessment has been made which offers readers an in-depth and accurate analysis. Market projections have been offered in terms of value (US$ Mn). Stakeholders of this report include companies and intermediaries engaged in research & development, manufacture, and marketing of products prescribed in the treatment of various skin conditions.

The global prescription dermatology therapeutics market has been studied for the forecast period from 2018 to 2026. For research, 2017 has been considered as the base year and 2016 as the historical year. The global prescription dermatology therapeutics market report comprises an elaborate executive summary that provides overall information about various segments of the market. The report provides a detailed competitive landscape, by major players operating in this market along with their shares (value %) of the global prescription dermatology therapeutics market for 2017. The report also provides detailed company profiles of emerging market players operating in the global prescription dermatology therapeutics market.

The market overview section comprises impact factors such as key market dynamics including drivers, restraints, and opportunities, affecting the global prescription dermatology therapeutics market. These factors are likely to aid stakeholders establish a strong foothold in the global prescription dermatology therapeutics market. Furthermore, the market overview section comprises key industry events, pipeline analysis, key mergers & acquisitions across the dermatology industry, epidemiology analysis of the skin diseases, product portfolio overview of leading players, and market attractiveness analysis in the global prescription dermatology therapeutics market. The market attractiveness analysis provides a graphical view comparing the expansion and market dynamics in various segments and countries to identify the most attractive market.

Scope

The global prescription dermatology therapeutics market has been segmented based product type, distribution channel, and region. In terms of product type, the global market has been classified into acne & rosacea drugs, psoriasis drugs, dermatitis & seborrhea drugs, fungal infection drugs, skin cancer, and others. In terms of distribution channel, the global prescription dermatology therapeutics market has been categorized into hospital pharmacies, retail pharmacies, and mail order pharmacies.

In terms of region, the global prescription dermatology therapeutics market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Moreover, quantitative analysis for major countries comprising the U.S., Canada, Germany, France, the U.K., Italy, Spain, Russia, China, Japan, India, and Australia & New Zealand has also been provided in the report. A detailed qualitative analysis of factors responsible for driving and restraining the global market in various regions has been provided in this section.

The report provides a detailed outline/blueprint of the global prescription dermatology therapeutics market which is expected to assist new companies establish their presence and companies to expand their share in the market. The report concludes with the company profiles section, which includes company overview, financial overview, SWOT analysis, product portfolio, business strategies, and recent developments of key players.

Competitive landscape

Major players operating in the global prescription dermatology therapeutics market include AbbVie, Inc., Janssen Biotech, Inc., Novartis AG, Amgen, Inc., Celgene Corporation, Pfizer, Inc., LEO Pharma A/S, Eli Lilly and Company, Bausch Health Companies, Inc., Sun Pharmaceuticals Ltd., Aclaris Therapeutics, Inc., and Aurobindo Pharma Ltd.

Note: Product cover images may vary from those shown
2 of 2
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Prescription Dermatology Therapeutics Market

4. Market Overview
4.1. Introduction
4.1.1. Product Type Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Prescription Dermatology Therapeutics Market Analysis and Forecast, 2016-2026
4.4.1. Market Revenue Projections (US$ Mn)

5. Market Outlook
5.1.Pipeline Analysis
5.2.Key Mergers & Acquisitions
5.3.Disease Prevalence & Incidence Rate globally with key countries

6. Global Prescription Dermatology Therapeutics Market Analysis and Forecast, by Product Type
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Product Type, 2016-2026
6.3.1. Acne & Rosacea Drugs
6.3.2. Psoriasis Drugs
6.3.3. Dermatitis & Seborrhea Drugs
6.3.4. Fungal Infection Drugs
6.3.5. Skin Cancer Drugs
6.3.6. Others
6.4. Market Attractiveness, by Product Type

7. Global Prescription Dermatology Therapeutics Market Analysis and Forecast, by Distribution Channel
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Distribution Channel, 2016-2026
7.3.1. Hospital Pharmacies
7.3.2. Retail Pharmacies
7.3.3. Mail Order Pharmacies
7.4. Market Attractiveness, by Distribution Channel

8. Global Prescription Dermatology Therapeutics Market Analysis and Forecast, by Region
8.1. Key Findings
8.2. Market Value Forecast, by Region
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness, by Country/Region

9. North America Prescription Dermatology Therapeutics Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. Market Value Forecast, by Product Type, 2016-2026
9.2.1. Acne & Rosacea Drugs
9.2.2. Psoriasis Drugs
9.2.3. Dermatitis & Seborrhea Drugs
9.2.4. Fungal Infection Drugs
9.2.5. Skin Cancer Drugs
9.2.6. Others
9.3. Market Value Forecast, by Distribution Channel, 2016-2026
9.3.1. Hospital Pharmacies
9.3.2. Retail Pharmacies
9.3.3. Mail Order Pharmacies
9.4. Market Value Forecast, by Country, 2016-2026
9.4.1. U.S.
9.4.2. Canada
9.5. Market Attractiveness Analysis
9.5.1. By Product Type
9.5.2. By Distribution Channel
9.5.3. By Country

10. Europe Prescription Dermatology Therapeutics Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Product Type, 2016-2026
10.2.1. Acne & Rosacea Drugs
10.2.2. Psoriasis Drugs
10.2.3. Dermatitis & Seborrhea Drugs
10.2.4. Fungal Infection Drugs
10.2.5. Skin Cancer Drugs
10.2.6. Others
10.3. Market Value Forecast, by Distribution Channel, 2016-2026
10.3.1. Hospital Pharmacies
10.3.2. Retail Pharmacies
10.3.3. Mail Order Pharmacies
10.4. Market Value Forecast, by Country/Sub-region, 2016-2026
10.4.1. Germany
10.4.2. U.K.
10.4.3. France
10.4.4. Spain
10.4.5. Italy
10.4.6. Rest of Europe
10.5. Market Attractiveness Analysis
10.5.1. By Product Type
10.5.2. By Distribution Channel
10.5.3. By Country/Sub-region

11. Asia Pacific Prescription Dermatology Therapeutics Market Analysis and Forecast
11.1.Introduction
11.1.1. Key Findings
11.2.Market Value Forecast, by Product Type, 2016-2026
11.2.1. Acne & Rosacea Drugs
11.2.2. Psoriasis Drugs
11.2.3. Dermatitis & Seborrhea Drugs
11.2.4. Fungal Infection Drugs
11.2.5. Skin Cancer Drugs
11.2.6. Others
11.3.Market Value Forecast, by Distribution Channel, 2016-2026
11.3.1. Hospital Pharmacies
11.3.2. Retail Pharmacies
11.3.3. Mail Order Pharmacies
11.4.Market Value Forecast, by Country/Sub-region, 2016-2026
11.4.1. China
11.4.2. Japan
11.4.3. India
11.4.4. Australia & New Zealand
11.4.5. Rest of Asia Pacific
11.5.Market Attractiveness Analysis
11.5.1. By Product Type
11.5.2. By Distribution Channel
11.5.3. By Country/Sub-region

12. Latin America Prescription Dermatology Therapeutics Market Analysis and Forecast
12.1.Introduction
12.1.1. Key Findings
12.2.Market Value Forecast, by Product Type, 2016-2026
12.2.1. Acne & Rosacea Drugs
12.2.2. Psoriasis Drugs
12.2.3. Dermatitis & Seborrhea Drugs
12.2.4. Fungal Infection Drugs
12.2.5. Skin Cancer Drugs
12.2.6. Others
12.3.Market Value Forecast, by Distribution Channel, 2016-2026
12.3.1. Hospital Pharmacies
12.3.2. Retail Pharmacies
12.3.3. Mail Order Pharmacies
12.4.Market Value Forecast, by Country/Sub-region, 2016-2026
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
12.5.Market Attractiveness Analysis
12.5.1. By Product Type
12.5.2. By Distribution Channel
12.5.3. By Country/Sub-region

13. Middle East & Africa Prescription Dermatology Therapeutics Market Analysis and Forecast
13.1.Introduction
13.1.1. Key Findings
13.2.Market Value Forecast, by Product Type, 2016-2026
13.2.1. Acne & Rosacea Drugs
13.2.2. Psoriasis Drugs
13.2.3. Dermatitis & Seborrhea Drugs
13.2.4. Fungal Infection Drugs
13.2.5. Skin Cancer Drugs
13.2.6. Others
13.3 Market Value Forecast, by Distribution Channel, 2016-2026
13.3.1. Hospital Pharmacies
13.3.2. Retail Pharmacies
13.3.3. Mail Order Pharmacies
13.4.Market Value Forecast, by Country/Sub-region, 2016-2026
13.4.1. GCC Countries
13.4.2. South Africa
13.4.3. Rest of Middle East & Africa
13.5.Market Attractiveness Analysis
13.5.1. By Product Type
13.5.2. By Distribution Channel
13.5.3. By Country/Sub-region

14. Competition Landscape
14.1.Market Player - Competition Matrix (By Tier and Size of companies)
14.2.Market Share Analysis By Company (2017)
14.3. Company Profiles
14.3.1. AbbVie, Inc.
14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.1.2. Product Portfolio
14.3.1.3. SWOT Analysis
14.3.1.4. Financial Overview
14.3.1.5. Strategic Overview
14.3.2. Janssen Biotech, Inc.
14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.2.2. Product Portfolio
14.3.2.3. SWOT Analysis
14.3.2.4. Financial Overview
14.3.2.5. Strategic Overview
14.3.3. Novartis AG
14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.3.2. Product Portfolio
14.3.3.3. SWOT Analysis
14.3.3.4. Financial Overview
14.3.3.5. Strategic Overview
14.3.4. Amgen, Inc.
14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.4.2. Product Portfolio
14.3.4.3. SWOT Analysis
14.3.4.4. Financial Overview
14.3.4.5. Strategic Overview
14.3.5. Celgene Corporation
14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.5.2. Product Portfolio
14.3.5.3. SWOT Analysis
14.3.5.4. Financial Overview
14.3.5.5. Strategic Overview
14.3.6. Pfizer, Inc.
14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.6.2. Product Portfolio
14.3.6.3. SWOT Analysis
14.3.6.4. Financial Overview
14.3.6.5. Strategic Overview
14.3.7. LEO Pharma A/S
14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.7.2. Product Portfolio
14.3.7.3. SWOT Analysis
14.3.7.4. Financial Overview
14.3.7.5. Strategic Overview
14.3.8. Eli Lilly and Company
14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.8.2. Product Portfolio
14.3.8.3. SWOT Analysis
14.3.8.4. Financial Overview
14.3.8.5. Strategic Overview
14.3.9. Bausch Health Companies, Inc.
14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.9.2. Product Portfolio
14.3.9.3. SWOT Analysis
14.3.9.4. Financial Overview
14.3.9.5. Strategic Overview
14.3.10. Sun Pharmaceuticals Ltd.
14.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.10.2. Product Portfolio
14.3.10.3. SWOT Analysis
14.3.10.4. Financial Overview
14.3.10.5. Strategic Overview
14.3.11. Aclaris Therapeutics, Inc.
14.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.11.2. Product Portfolio
14.3.11.3. SWOT Analysis
14.3.11.4. Financial Overview
14.3.11.5. Strategic Overview
14.3.12. Aurobindo Pharma Ltd
14.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.12.2. Product Portfolio
14.3.12.3. SWOT Analysis
14.3.12.4. Financial Overview
14.3.12.5. Strategic Overview
Note: Product cover images may vary from those shown
3 of 2

Loading
LOADING...

Adroll
adroll